Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Key Points

• Genmab A/S experienced a significant decrease in short interest, dropping 25.2% in August, totaling 22,800 shares as of August 15th.
• The company reported an earnings per share (EPS) of $5.42 for the last quarter, exceeding analysts' estimates of $3.99.
• As of recent trading, Genmab's stock is up by $15.00 to $274.50 with a market cap of $18.14 billion.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant decrease in short interest in the month of August. As of August 15th, there was short interest totaling 22,800 shares, adecreaseof25.2% from the July 31st total of 30,500 shares. Based on an average daily volume of 1,800 shares, the days-to-cover ratio is currently 12.7 days. Based on an average daily volume of 1,800 shares, the days-to-cover ratio is currently 12.7 days.

Genmab A/S Price Performance

Shares of OTCMKTS:GNMSF traded up $15.00 during trading on Monday, reaching $274.50. 3,921 shares of the stock were exchanged, compared to its average volume of 250. Genmab A/S has a 1-year low of $170.00 and a 1-year high of $279.52. The stock has a fifty day moving average of $225.22 and a two-hundred day moving average of $212.33. The firm has a market cap of $18.14 billion, a price-to-earnings ratio of 13.78 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.